HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antigingivitis agent-by-agent final formula performance standards suggested by FDA cmte.

This article was originally published in The Rose Sheet

Executive Summary

ANTIGINGIVITIS AGENT-SPECIFIC FINAL FORMULA PERFORMANCE STANDARDS PREFERABLE over the development of performance standards for final formulations by pharmacological class, Max Listgarten, DDS, University of Pennsylvania, said at an Oct. 30 meeting of FDA's Nonprescription Drugs Advisory Committee's Dental Plaque Subcommittee in Gaithersburg, Md. The meeting continued the subcommittee's ongoing effort to propose a framework for an antigingivitis/antiplaque products OTC monograph. One issue discussed by the subcommittee was the development of appropriate performance standards for final formulations of gingivitis products.
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS004816

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel